Summary
Dyspnea in patients with cancer is a common symptom and is generally associated with anxiety. It limits patients' activities of daily living and adversely affects not only patients, but also caregivers. It remains a difficult symptom to manage, despite recent advances in cancer treatment and the increasing evidence available. Different pharmacological approaches such as opioids, and nonpharmacological interventions including oxygen, fun, exercise, pulmonary rehabilitation, acupuncture, acupressure and cognitive-behavioral therapies are used to manage dyspnea. Symptom management and supportive therapies given by oncology nurses become important in patients with cancer who experience dyspnea. There are limited number of publications about the management of dyspnea in Turkish oncology nursing literature. This literature review aims to inform nurses about cancer patients with dyspnea.Introduction
The definition, underlying pathophysiological causes, and identification of dyspnea will be discussed in the introduction section of this review article. Pharmacological and non-pharmacological approaches for the management of dyspnea in cancer patients will be examined based on randomized controlled studies. Roles and responsibilities of nurses in the management of dyspnea will be summarized in the last section.Dyspnea is defined as a feeling of respiratory distress and difficult breathing; patients often describe this symptom as breathlessness, difficulty breathing, or shortness of breath.[1] Prevalence of dyspnea in cancer patients has been reported to be 21–90%, depending on the stage of the cancer, and is reported more frequently in the last 6 weeks of life.[2,3] One of the most frightening and discomforting symptoms of cancer, dyspnea initially occurs in patients only during periods of activity. Intensity and frequency of dyspnea increase with progress of the disease, restricting patient's daily life functions and causing a decrease in quality of life (QOL).[1,4,5]
Although the causes of common symptoms such as pain, nausea, and vomiting in patients with cancer are known, underlying causes of dyspnea are not completely understood.[3] The pathophysiology of dyspnea is multifactorial. This complex pathophysiology can be conceptually summarized into 3 components: (a) increase in respiratory effort in order to overcome a mechanical impairment (e.g. obstructive or restrictive lung disease, pleural effusion); (b) increase in proportion of respiratory muscle required to maintain normal workload (e.g. neuromuscular weakness, cancer cachexia, etc.); and (c) increase in ventilatory requirements (hypoxemia, hypercapnia, metabolic acidosis, anemia, etc.).[3,6] Causes of dyspnea in cancer patients can be grouped as directly or indirectly associated with cancer, induced by cancer treatment, and not associated with cancer.[7] Causes that are directly associated with cancer include: coverage of pulmonary parenchyma by primary or metastatic cancer, lymphangitis carcinomatosis, airway obstruction created by tumors, pleural tumors, pleural effusion, pericardial effusion, abdominal ascites, hepatomegaly, phrenic nerve palsy, multiple tumor microemboli, pulmonary leukostasis, and superior vena cava syndrome. Indirect causes of dyspnea associated with cancer include cachexia, electrolyte imbalance, anemia, pneumonia, pulmonary aspiration, pulmonary embolism, and paraneoplastic syndrome. Cancer treatment-induced causes of dyspnea include pulmonary fibrosis associated with chemotherapy, cardiomyopathy associated with chemotherapy, radiation pneumonia, and problems associated with surgery.[3] Non-cancer causes of dyspnea include asthma, chronic obstructive pulmonary disease (COPD), congestive heart failure, pneumothorax, anxiety, obesity, neuromuscular disease, and pulmonary vascular disease.[2,3]
Diagnosis of Dyspnea
There is no reliable, objective measure of dyspnea; patient
self-report is only reliable indicator of dyspnea in
clinical practice. Respiratory rate, oxygen saturation,
and arterial blood gas (ABG) determinations neither
correlate with nor measure dyspnea. Patients may be
hypoxemic, but not dyspneic, or dyspneic, but not hypoxemic.[3] In clinical research setting, dyspnea may
be measured in a number of ways. Functional assessment
tools such as shuttle walking test and reading
aloud of numbers have been validated. When functional
assessment is difficult, tools such as the Visual
Analog Scale (VAS)[8] and Borg[9] scale can be used.
If focus is more on the impact of dyspnea on patient
QOL, then a multidimensional tool should be considered
such as the Lung Cancer Symptom Scale (LCSS),
the Dyspnea Exertion Scale (DES), or breathlessnessspecific
questionnaires such as the Cancer Dyspnea
Scale (CDS).[5]
Accurate assessment is very important for clinical management of dyspnea. Patient history and physical examination are essential components. Drugs used by patient, smoking status, profession/occupation, and radiotherapy or chemotherapy treatments offer important clues for assessing dyspnea. In addition, patient psychosocial and spiritual stress must be well understood because of cognitive and emotional factors that can affect dyspnea. Use of pulse oximetry, complete blood count (CBC), and chest radiography methods in the physical examination, are helpful to clearly understand underlying pathophysiology. Although use of advanced tests such as ABG analysis, pulmonary function tests, computed tomography (CT), echocardiography and ventilation-perfusion scanning increases medical costs, they are reported to be effective.[5]
Management of Dyspnea
Use of a multidisciplinary team approach, application
of combination of pharmacological and non-pharmacological
treatments, and education of patients/
relatives are needed to manage dyspnea with advanced
cancer.[4,5,10]
Pharmacological Approaches
Opioids
Opioids have been shown to be the most effective pharmacological
agents for symptomatic control of dyspnea.
Morphine, fentanyl, hydromorphone and oxycodone
are some of the most common opioids used to manage
dyspnea. The mechanism of how these medications affect
dyspnea is the same as that of pain relief: they reduce
ventilation, anxiety, and the central perception of
dyspnea (and pain) by binding to opioid receptors.[10]
Morphine is the most common opioid used to relieve
dyspnea, and can be administered via oral, parenteral,
and nebulized routes. There is no standardized dose,
administration scheme or administration method of
morphine.[10] Morphine is reported to be effective
in management of dyspnea without significant reduction
in patient respiratory rate, respiratory effort, and
oxygen saturation value.[2] Although oral or intravenous
route is currently the treatment of choice, many
randomized, controlled studies have been performed
to determine efficacy of nebulized morphine.[5,10]
These studies have found that there is no significant
difference between nebulized morphine and nebulized
placebo; therefore, it is not recommended as first line
treatment at this time.
Anticholinergics and Beta2-Agonists
Respiratory resistance increases due to bronchospasm,
airway obstruction, effusion, and accumulation of secretions.
Inhaled beta2-agonists or anticholinergics
have been reported to assist in treatment of lung cancer
patients who experienced sudden bronchospasm. Bronchodilators can reduce breathing effort. Anticholinergics
administrated orally, subcutaneously, transdermally
or inhaled such as glycopyrrolate, atropine,
scopolamine, and hyoscyamine, are recommended to
reduce secretions.[10]
Anxiolytics
Like opioids, benzodiazepines have been used to help
provide relief from dyspnea in cancer patients. Although
their effects do not directly change breathing,
they are effective for anxiety, panic and fear symptoms
often associated with dyspnea. There is a lack
of evidence regarding the effect of benzodiazepines
in the management of dyspnea; however, lorazepam,
diazepam, and midazolam have been reported to be
effective in reducing anxiety-induced dyspnea.[2,5]
Benzodiazepines, which exhibit their effects on gamma-
aminobutyric acid (GABA) receptors, can be used
for sedative, hypnotic, muscle relaxant anxiolytic, and
anticonvulsant purposes. When benzodiazepines are
administered in normal dose ranges they do not affect
respiratory rate, but high doses are reported to
suppress ventilation rate slightly. Navigante and et al.
(2006) performed a randomized, single-blind study
using midazolam as an adjunct therapy to morphine.
They found that the combination of this benzodiazepine
with morphine had a positive effect on dyspnea
with minimal effect on somnolence.[11] In contrast
to these results, Simon and et al. (2010) stated that
there is no evidence to support the efficacy of benzodiazepines
in the palliation of dyspnea in their metaanalysis.[5,12] More randomized, controlled studies
aimed at assessing the efficacy of benzodiazepines
used in conjunction with other opioids need to be
performed.
Diuretics
Furosemide is a loop diuretic agent used in treatment of
heart failure, pulmonary edema, acid and edema. There
has been recent literature on the efficacy of inhaled furosemide
for treatment of dyspnea. Studies performed
using inhaled furosemide have been small and uncontrolled,
but results have been positive.[13,14] Wilcock
et al. (2008) conducted a randomized controlled study
and reported that nebulized furosemide had no impact
on dyspnea with cancer patients and did not cause any
side effects.[15] Despite participants stating that they
felt relief from the dyspnea, there were no statistically
significant results in another randomized controlled trial examining the effect of nebulized furosemide in
the management of cancer-related dyspnea.[14] Larger,
randomized and controlled studies need to be performed
and their results analyzed before guidelines to
use these medications in treatment of dyspnea can bee
recommended.
Non-Pharmacologic Approaches
As physical, psychosocial, emotional, and functional
factors influence the development of dyspnea, pharmacological
approaches alone are not sufficient to manage
it. Acupuncture, acupressure, neuromuscular electrical
stimulation, external nasal dilator strips, pulmonary
rehabilitation, regular exercise programs, use of supplemental
oxygen and fan have been reported to manage
dyspnea.[4,5,16–18] In addition, nurse counseling,
effective respiratory-cough exercises, patient education
programs, relaxation techniques, and coping strategies
have been reported to make significant contributions
to alleviating dyspnea.[8,9]
Acupuncture and Acupressure
Acupuncture is one of the oldest complementary treatments
in the world and originated in China and other
Asian countries. It has been argued that acupuncture
stimulates sensory receptors in the body by increasing
the level of analgesia or endorphins in the central nervous
system (CNS) and provides sedation, supports the
immune system, and maintains homeostasis.[19]
Acupuncture professionals argue that there are meridians, or energy paths, that link the different parts of the body and correspond to neurovascular connective tissue. According to a hypothesis, acupuncture stimulates the somatosensory system with the release of endogenous opioids. It is known that acupuncture causes a release of neurotransmitters, neuropeptides and other hormones, and produces a common effect on body functions leading to electrophysiological changes in different areas such as the autonomic nervous system (ANS), pituitary gland, hypothalamus and other parts of the brain.[20] Acupressure is another therapy technique that is similar to acupuncture; it is practiced by applying physical pressure with fingers, hand, palms, elbows, and knee to selected points on the body.[21] Considering the common effects, it is expected that acupuncture and acupressure would provide positive results for symptom management of cancer and cancer- related treatments.[20]
It is reported that acupressure used for dyspnea significantly reduced dyspnea scores in patients with COPD. A randomized controlled study using patients with COPD compared sham acupressure and self-administered acupressure and reported that there was a 1/3 reduction in VAS dyspnea scores of patients in the acupressure group and a 20% decrease in the placebo group (sham acupressure).[22] Another study conducted in patients with COPD suffering chronic dyspnea found that acupressure applied to the correct pressure points decreased dyspnea and anxiety, and also increased activity tolerance.[23]
In the literature, only 1 acupuncture study was conducted for dyspnea in cancer patients. Although this study had no control group, it supported the positive effects of acupuncture. In that study, 30 patients with cancer received a single session of acupuncture and mean VAS scores quickly decreased from 42 to 24 after 10 minutes of acupuncture intervention, and this effect continued for the duration of 6-hour follow-up. After the 6-hour follow-up, symptom scores returned to baseline values.[24]
Pulmonary Rehabilitation and Exercise Programs
Pulmonary symptoms including exercise intolerance,
dyspnea, and fatigue are often encountered in patients
with cancer. These symptoms originate from the nature
of the disease itself or indirectly related causes, and
lead to an increase in symptom burden in patients at
later stages. Pulmonary rehabilitation is a multidisciplinary
therapeutic approach that has beneficial effects
on respiratory symptoms and combines patient education
and psychosocial support. It has been reported
that pulmonary rehabilitation improves exercise performance
and physiological capacity in patients with
lung cancer.[25,26]
Lack of muscle training in cancer patients with dyspnea results in the production of low rates lactic acid and exercise intolerance. Although exercise education is an important component of pulmonary rehabilitation, patients with dyspnea experience significant difficulties participating in such activities.[27] It has been stated that exercise programs used in advanced stages of COPD patients reduce difficulty of breathing and alleviate dyspnea. In addition, these exercise programs are thought to be effective for cancer patients with dyspnea.[27,28]
A pulmonary rehabilitation study conducted with lung cancer patients demostrated significant improvements in symptoms.[29] Morris et al. (2009) performed a study in patients with different types of cancer and reported that pulmonary rehabilitation training involving short aerobic exercises had been particularly effective for rehabilitation of pulmonary symptoms.[30] Wenzel's (2010) randomized controlled study comparing effects of exercise and routine activity stated that patients in the exercise group had lower emotional stress levels. That study also found that increased aerobic exercise was associated with reduced fatigue scores.[31]
The Use of Neuromuscular Electrical Stimulus
Neuromuscular electrical stimulus is an application
that seeks to regain function of muscles by stimulating
nerves in the muscles. Neuromuscular electrical
impulses produce high-intensity muscle contractions
by imitating low and high-intensity standard resistance
exercise. These impulses encourage patients to
continue treatment and progress by increasing muscle
power with a passive process. Neuromuscular electrical
stimulation studies have largely been conducted in
patients with COPD.[32] Further studies in this area
are needed to determine the effects on cancer patients
with dyspnea.
The Use of External Nasal Dilator Strips
Adhesive bands containing a central elastic strip are
often used to prevent snoring and to support breathing
through the nose during exercise. For the first time,
Neuenschwander et al. (2006) used external nasal dilator
strips in patients with cancer with the goal of reducing
dyspnea-induced cumulated effort of continuous
breathing. Study results indicated that there was
no serious side effect to use of nasal strips and most
patients were willing to use these bands. In that study,
the authors concluded that the bands would be effective
in reducing fatigue in patients and would provide
beneficial effects in the management of dyspnea.[17]
Oxygen Therapy and the Use of Portable Fans
Oxygen therapy is still one of the basic approaches used
in the treatment of severe dyspnea and is often applied
for long-term severe hypoxemia. Oxygen therapy is
generally prescribed for patients who have lifespan of
less than 3 months, and for severe hypoxemia in the
terminal stage, although it restricts the level of activity. [33,34] Room air and oxygen therapy were compared
in a study conducted with 31 patients with lung cancer
or other metastatic cancer, and stated that there was no
significant difference between the groups in terms of
dyspnea.[35]
In another randomized controlled study conducted with 12 patients with lung cancer and dyspnea, half of participants walked with oxygen-enriched air and the other half with medical air. Although the group receiving oxygen-enriched air needed less rest during the walk test, this difference was not statistically significant. Oxygen-enriched air caused a reduction in exercise- induced respiratory rate compared to the medical air, but there was no significant difference between groups in terms of oxygen saturation.[36]
Cold air applied directly to areas of the face such as cheeks, nasal mucosa, and pharynx, was seen to reduce dyspnea for the first time in the Schwartzste (1987) study. Although the effect of fan use in reducing dyspnea has not been explained clearly, it is accepted that cold receptors would change respiration rate by stimulating the trigeminal nerve and reducing sensation with sensory effect. Studies about the use of a fan for palliation of dyspnea encourage the evidence. There was a significant decrease in perception of dyspnea in a randomized controlled trial that examined the impact of a fan directly applied to the cheeks, conducted with 49 patients (15 participants diagnosed with cancer). [37] Current studies in the management of dyspnea show that traditional oxygen therapy is not superior to the use of a fan.[38,39]
The Multidisciplinary Team Approach
Despite recent advances in pharmacology, management
of dyspnea in the last period of life is difficult.
Progressive dyspnea indicates poor prognosis. It also
creates need for sedation and hospitalization to provide
symptom control in the last stage of life. The establishment
of specialized palliative care can serve to train/
support health professionals as well as provide more
comfort for patients at the end of life.[40] Specialized
palliative care units serve to manage complex and uncontrolled
symptoms, support patients, maintain patient
QOL, provide means to discuss best options for
patients and their relatives within the framework of
end of life care, educate other clinics that treat terminal
stage cancer patients, and to give a standard of care according
to guidelines to other clinics.[41]
The Roles and Responsibilities of Nurses
Nurses are a key member of the palliative care team
and have important roles and responsibilities in the
care and treatment of cancer patients with dyspnea.
Nurses can increase the level of independence in activities
of daily living (ADL) and can provide important
contributions to patient QOL through close monitoring,
administering treatments, oxygen support, appropriate
positioning techniques, pursed lip and diaphragmatic
exercises, postural drainage principles, clearance
of secretions, intermittent ventilation of patient rooms,
using a fan, instruction in energy conservation techniques,
encouragement of patients in daily exercises
and applyingng adequate/balanced diet.[2,4,8]
Dyspnea may be frightening, not just for patients, but also for caregivers. As the disease progresses, the severity of dyspnea and increased stress levels in patients adversely affect the QOL of both patients and caregivers. Patient relatives or spouse experience serious anxiety and despair because of patient dyspnea suffering.[42] Caregivers often think that management of dyspnea is very challenging since they have no strategies for how to alleviate it.[43] When approaching dyspnea with a holistic perspective, the impact of dyspnea on the lives of caregivers should also be adressed. Nursing care plans should also focus on the anxiety level of patient relatives, as well as psychosocial stress of patients and caregivers.[41]
A randomized controlled study was conducted on 20 patients who had small cell and non-small cell lung cancer, had completed their chemotherapy and radiotherapy, and received 1-hour sessions from a nurse for 3-6 weeks that included breathing re-training; counseling; and relaxation, coping and adaptation strategies. The control group did not receive any intervention. Patients in the intervention group had significant improvement in dyspnea, dyspnea-induced stress level and functional capacity compared to the control group at 3 months.[29]
Consequently, nurses can provide significant contributions to management of dyspnea by eliminating the dyspnea-induced anxiety and fear that occur in patient and caregivers by applying behavioral and psychotherapeutic approaches, teaching effective-coping strategies, following patients at their home, making regular phone calls, giving advanced directives and supporting patients and their families in the critical decision-making process.[8]
Conflict of interest: None declared.
References
1) Mercadante S, Casuccio A, Fulfaro F. The course of
symptom frequency and intensity in advanced cancer
patients followed at home. J Pain Symptom Manage
2000;20(2):104–12.
2) Akyolcu N. Kanserli hastalarda dispne ve hemşirelik
bakımı. C.Ü. Hemşirelik Yüksekokulu Dergisi
2002;6(1):1–8.
3) Thomas JR, von Gunten CF. Clinical management of
dyspneoa. Lancet Onco 2002;3(4):223–8.
4) Ben-Aharon I, Gafter-Gvili A, Paul M, Leibovici L,
Stemmer SM. Interventions for alleviating cancerrelated
dyspnea: a systematic review. J Clin Oncol
2008;26(14):2396–404.
5) Thomas S, Bausewein C, Higginson I, Booth S. Breathlessness
in cancer patients - implications, management
and challenges. Eur J Oncol Nurs 2011;15(5):459–69.
6) Paice AJ. Oncology nursing, assesment and clinical
care: Symptom management. Miaskowski C, Buchsel
P, editors. St. Louis: Mosby; 1999.
7) Reinke EF, Hoffman LA. Assesment and management
of clinical problems: respiratory system. In: Lewis SM,
Heitkemper MM, Dirksen S, editors. Medical surgical
nursing. St. Louis: Mosby; 2000.
8) Bredin M, Corner J, Krishnasamy M, Plant H, Bailey
C, A'Hern R. Multicentre randomised controlled trial
of nursing intervention for breathlessness in patients
with lung cancer. BMJ 1999;318(7188):901–4.
9) Moore S, Corner J, Haviland J, Wells M, Salmon E, Normand
C, et al. Nurse led follow up and conventional
medical follow up in management of patients with lung
cancer: randomised trial. BMJ 2002;325(7373):1145.
10) LeGrand SB. Dyspnea: the continuing challenge of palliative
management. Curr Opin Oncol 2002;14(4):394–8.
11) Navigante AH, Cerchietti LC, Castro MA, Lutteral
MA, Cabalar ME. Midazolam as adjunct therapy to
morphine in the alleviation of severe dyspnea perception
in patients with advanced cancer. J Pain Symptom
Manage 2006;31(1):38–47.
12) Simon ST, Higginson IJ, Booth S, Harding R, Bausewein
C. Benzodiazepines for the relief of breathlessness
in advanced malignant and non-malignant
diseases in adults. Cochrane Database Syst Rev
2010;(1):CD007354.
13) Shimoyama N, Shimoyama M. Nebulized furosemide
as a novel treatment for dyspnea in terminal cancer
patients. J Pain Symptom Manage 2002;23(1):73–6.
14) Kallet RH. The role of inhaled opioids and furosemide for the treatment of dyspnea. Respir Care
2007;52(7):900–10.
15) Wilcock A, Walton A, Manderson C, Feathers L, El
Khoury B, Lewis M, et al. Randomised, placebo controlled
trial of nebulised furosemide for breathlessness
in patients with cancer. Thorax 2008;63(10):872–5.
16) Morris GS, Gallagher GH, Baxter MF, Brueilly KE,
Scheetz JS, Ahmed MM, et al. Pulmonary rehabilitation
improves functional status in oncology patients.
Arch Phys Med Rehabil 2009;90(5):837–41.
17) Neuenschwander H, Molto A, Bianchi M. External
nasal dilator strips (ENDS) may improve breathlessness
in cancer patients. Support Care Cancer
2006;14(4):386–8.
18) Vickers AJ, Feinstein MB, Deng GE, Cassileth BR.
Acupuncture for dyspnea in advanced cancer: a
randomized, placebo-controlled pilot trial [ISRCTN89462491].
BMC Palliat Care 2005;4:5.
19) Rickards LD. Therapeutic needling in osteopathic
practice: An evidence-informed perspect. International
Journal of Osteopathic Medicine 2009;12(1):2–13.
20) Kasymjanova G, Grossman M, Tran T, Jagoe RT, Cohen
V, Pepe C, et al. The potential role for acupuncture
in treating symptoms in patients with lung cancer:
an observational longitudinal study. Curr Oncol
2013;20(3):152–7.
21) Hakverdioğlu G, Türk G. Akupressur. Hacettepe Üniversitesi
Hemşirelik Yüksekokulu Dergisi 2006;43–7.
22) Maa SH, Gauthier D, Turner M. Acupressure as an
adjunct to a pulmonary rehabilitation program. J Cardiopulm
Rehabil 1997;17(4):268–76.
23) Wu HS, Wu SC, Lin JG, Lin LC. Effectiveness of acupressure
in improving dyspnoea in chronic obstructive
pulmonary disease. J Adv Nurs 2004;45(3):252–9.
24) Filshie J, Penn K, Ashley S, Davis CL. Acupuncture for
the relief of cancer-related breathlessness. Palliat Med
1996;10(2):145–50.
25) Bobbio A, Chetta A, Ampollini L, Primomo GL, Internullo
E, Carbognani P, et al. Preoperative pulmonary
rehabilitation in patients undergoing lung resection
for non-small cell lung cancer. Eur J Cardiothorac
Surg 2008;33(1):95–8.
26) Spruit MA, Janssen PP, Willemsen SC, Hochstenbag
MM, Wouters EF. Exercise capacity before and after
an 8-week multidisciplinary inpatient rehabilitation
program in lung cancer patients: a pilot study. Lung
Cancer 2006;52(2):257–60.
27) Simon ST, Bausewein C. Management of refractory
breathlessness in patients with advanced cancer. Wien
Med Wochenschr 2009;159(23-24):591–8.
28) Bausewein C, Booth S, Gysels M, and Higginson I.
Nonpharmacological interventions for breathlessness in advanced stages of malignant and non-malignant
diseases. Cochrane Database of Systematic Reviews,
2008.
29) Corner J, Plant H, A'Hern R, Bailey C. Non-pharmacological
intervention for breathlessness in lung cancer.
Palliat Med 1996;10(4):299–305.
30) Morris GS, Gallagher GH, Baxter MF, Brueilly KE,
Scheetz JS, Ahmed MM, et al. Pulmonary rehabilitation
improves functional status in oncology patients.
Arch Phys Med Rehabil 2009;90(5):837–41.
31) Wenzel J. Results of a home-based walking intervention
for patients undergoing cancer treatment. 16th
International Conference on Cancer Nursing. International
Society of Nurses in Cancer Care (ISNCC),
Georgia USA, 2010. Abstract available from. www.
isncc.org/files/PDF/16th_ICCN_Abstract_Book.pdf
(p. 24; 0–36).
32) Man WD, Kemp P, Moxham J, Polkey MI. Exercise and
muscle dysfunction in COPD: implications for pulmonary
rehabilitation. Clin Sci (Lond) 2009;117(8):281–91.
33) Gallagher R, Roberts D. A systematic review of oxygen
and airflow effect on relief of dyspnea at rest in patients
with advanced disease of any cause. J Pain Palliat Care
Pharmacother 2004;18(4):3–15.
34) McDonald CF, Crockett AJ, Young IH. Adult domiciliary
oxygen therapy. Position statement of the Thoracic
Society of Australia and New Zealand. Med J Aust
2005;182(12):621–6.
35) Bruera E, Sweeney C, Willey J, Palmer JL, Strasser F,
Morice RC, et al. A randomized controlled trial of
supplemental oxygen versus air in cancer patients with
dyspnea. Palliat Med 2003;17(8):659–63.
36) Ahmedzai SH, Laude E, Robertson A, Troy G, Vora V.
A double-blind, randomised, controlled Phase II trial
of Heliox28 gas mixture in lung cancer patients with
dyspnoea on exertion. Br J Cancer 2004;90(2):366–71.
37) Abernethy AP, McDonald CF, Frith PA, Clark K, Herndon
JE 2nd, Marcello J, et al. Effect of palliative oxygen
versus room air in relief of breathlessness in patients
with refractory dyspnoea: a double-blind, randomised
controlled trial. Lancet 2010;376(9743):784–93.
38) Galbraith S, Fagan P, Perkins P, Lynch A, Booth S.
Does the use of a handheld fan improve chronic dyspnea?
A randomized, controlled, crossover trial. J Pain
Symptom Manage 2010;39(5):831–8.
39) Cranston JM, Crockett A, Currow D. Oxygen therapy
for dyspnoea in adults. Cochrane Database of Systematic
Reviews, 2008.
40) Booth S. Improving the palliative care patients with
intractable breathlessness. PhD Thesis, University of
London, 2008.
41) Bausewein C, Booth S, Gysels M, Kühnbach R, Haberland
B, Higginson IJ. Understanding breathlessness:
cross-sectional comparison of symptom burden and
palliative care needs in chronic obstructive pulmonary
disease and cancer. J Palliat Med 2010;13(9):1109–18.